Company

Decipher Biosciences

Rocket Ship Rating

Rocket Ship Rating: 90 out of 100

Decipher Prostate provides clinicians and patients with genomic insights to help make more informed prostate cancer treatment decisions.

Also known as Decipher, DECIPHER BIOSCIENCES, INC.

Medical devices & diagnostics

Status: Operatingas of 2026-09-20Source (opens in a new tab)
Business model: B2B
Headquarters: San Diego, CA, United States
Customers: clinicians and patients
Legal name: DECIPHER BIOSCIENCES, INC.

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

Decipher Prostate provides clinicians and patients with genomic insights to help make more informed prostate cancer treatment decisions.

Funding snapshot

Total raised: $72.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Round, $8M2020-05-15

Funding rounds

Round, 2020: $8M2020-05-15, SEC form D sold, 35 investors
Round, 2019: $13M2019-03-29, SEC form D sold, 37 investors
Round, 2018: $3.2M2018-12-28, SEC form D sold, 37 investors
Round, 2018: $3.4M2018-10-04, SEC form D sold, 36 investors
Round, 2018: $2.7M2018-07-20, SEC form D sold, 41 investors
Round, 2018: $6.1M2018-04-09, SEC form D sold, 29 investors
Round, 2017: $4.9M2017-11-01, SEC form D sold, 30 investors
Round, 2017: $6.3M2017-06-19, SEC form D sold, 9 investors
Round, 2016: $25.4M2016-02-24, SEC form D sold, 27 investors

About the company

Status notes: Acquired by Veracyte March 2021

Products

Other: Decipher Prostate
Web: Decipher Prostate Genomic Classifier

Exit

Acquisition: 2021-03